|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,835,739: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,835,739, issued on December 28, 2004, to Hoechst Marion Roussel Inc., pertains to a novel method of enhancing drug absorption through the use of specific pharmaceutical compositions. The patent primarily claims a composition combining an active pharmaceutical ingredient (API), a selected carrier, and an absorption-enhancing agent. This patent has implications for drug delivery technologies, particularly those improving bioavailability of poorly soluble or permeability-limited drugs.
This report provides a comprehensive analysis of the patent’s scope and claims, contextualizes its place within the broader patent landscape, and assesses strategic considerations for stakeholders involved in pharmaceutical innovation and patent management.
1. Scope of Patent 6,835,739
1.1 Fundamental Technical Focus
- Core Innovation: The patent covers a pharmaceutical composition designed to enhance drug absorption, particularly through the gastrointestinal tract.
- Primary Components:
- An active pharmaceutical ingredient (API), especially poorly soluble or poorly permeable compounds.
- A carrier or excipient matrix.
- An absorption enhancer, which increases permeability or solubility.
1.2 Claims Overview
The patent contains 8 claims that vary from broad composition claims to method specific claims:
| Claim Type |
Description |
Key Elements |
| Claim 1 |
Broad composition claim |
API + carrier + absorption enhancer. |
| Claim 2-5 |
Dependent on Claim 1, specifying components |
Specific absorption enhancers, carriers, API parameters. |
| Claim 6 |
Method claim |
Method of preparing the composition, involving mixing or manufacturing steps. |
| Claim 7-8 |
Use claims |
Use of the composition for enhancing absorption of specific drugs. |
The broad claims target a general class of compositions with various absorption enhancers, whereas narrower claims specify particular APIs, carriers, or enhancer types.
1.3 Claim Scope Limitations
- Absorption Enhancers: The claims specify particular classes such as surfactants (e.g., bile salts), fatty acids, and certain polymeric agents.
- Manufacturing Methods: Claims include processes such as blending, coating, or nanoparticulate preparation.
- Targeted Application: Primarily directed at oral delivery systems but with potential applicability across other routes if specified.
2. Detailed Claim Analysis
2.1 Composition Claims
| Claim |
Scope |
Notable Limitations |
Implications |
| Claim 1 |
A composition comprising: (i) an API, (ii) a carrier, (iii) an absorption enhancer |
Broad; no restriction on specific component types |
Establishes foundational intellectual property; broad coverage of formulations aimed at absorption enhancement |
| Claim 2-5 |
Variations on Claim 1 specifying types of enhancers/carriers or API characteristics |
Specificity to certain classes or molecular sizes |
Narrower protection but enhances enforceability against specific product designs |
2.2 Method Claims
| Claim |
Scope |
Limitations |
Implications |
| Claim 6 |
A process for preparing the composition |
Standard mixing, stirring, or surface coating steps |
Protects manufacturing techniques; critical for process infringement evaluations |
| Claims 7-8 |
Use of the composition for enhancing absorption or bioavailability |
Specific therapeutic applications or drugs |
Extends patent’s influence into therapeutic claims |
2.3 Notable Components in Claims
| Component Type |
Examples |
Function in Claims |
Patent Position |
| Absorption enhancers |
Bile salts, fatty acids, surfactants |
Increase permeability or solubilization |
Central to patent’s novelty |
| Carriers |
Hydrophilic polymers, lipids, surfactants |
Facilitate API delivery |
Used to improve formulation stability and bioavailability |
3. Patent Landscape Assessment
3.1 Patent Families and Related Patents
| Patent Family Members |
Issue Dates |
Assignees |
Focus |
| US 6,835,739 |
Dec 28, 2004 |
Hoechst Marion Roussel Inc. |
Drug absorption enhancement compositions |
| EP Patent |
Corresponding European patent |
Hoechst |
Similar claims in European jurisdiction |
| WO Patent Applications |
Filed under PCT |
Various leading pharmaco companies |
Expanding protection to multiple jurisdictions |
3.2 Competitor and Innovation Trends
- Pre-Patent Environment: Prior to 2004, absorption enhancement was primarily addressed via surfactants and lipid formulations.
- Post-Patent Growth: Multiple subsequent patents have extended or circumvented aspects of this patent, focusing on nanoparticulate systems, lipid-based delivery vehicles, and targeted absorption pathways.
- Key Innovators: Companies such as GlaxoSmithKline, Pfizer, and Lilly have filed patents on advanced absorption technology, often citing or designing around US 6,835,739.
3.3 Citations and Influences
| Type |
Document |
Relationship |
Date |
Comments |
| Citing Patents |
Various |
Building upon or designing around |
2005–2015 |
Reflects influence in absorption-enhancement formulations |
| Cited Art |
Prior art such as US 5,641,515 (lipid formulations) |
Foundation for innovation |
1997 |
Demonstrates lineage of absorption technologies |
4. Comparative Technologies and Legal Status
| Technology Area |
Notable Patents |
Key Differentiators |
Status |
| Lipid-based delivery systems |
US 5,580,548 |
Lipid formulations for bioavailability |
Expired, foundational |
| Nanoparticle absorption |
US 7,134,592 |
Nanosized carriers, different methods |
Active, potentially overlapping |
| Permeation enhancers |
US 6,916,445 |
Focused on surfactants |
Expired or licensed |
Legal Status: The patent remains in force until December 2024, absent any extensions or legal challenges.
5. Strategic Considerations
| Aspect |
Implication |
| Infringement Risk |
Formulations employing similar absorption enhancers with comparable compositions may infringe if they fall within claim scope. |
| Patent Expiry |
Approaching expiration (December 2024), potential for generic or biosimilar development increases. |
| Design-Around Opportunities |
Alternative enhancers or modified compositions are viable due to broad initial claims. |
| Licensing and Partnerships |
Opportunity streams for patent holders, licensing for improved drug delivery systems. |
6. Deep Dive Into Technical and Commercial Relevance
| Key Area |
Details |
Impact |
| API Compatibility |
The patent covers poorly soluble drugs, including certain BCS class II and IV compounds |
Crucial for niche therapy areas such as oral peptides or peptides with limited permeability |
| Formulation Technologies |
Emphasis on combining absorption enhancers with carriers |
Guides formulation development strategies |
| Bioavailability Enhancement |
The patent's methodology supports increased systemic absorption, reducing doses, and improving patient compliance |
Commercially valuable for reformulation of existing drugs |
Conclusion
U.S. Patent 6,835,739 embodies a broad intellectual property framework for drug absorption enhancement compositions and methods. Its claims encompass a flexible class of formulations employing various absorption enhancers, carriers, and APIs, making it a foundational patent in oral delivery technology. The scope's breadth invites both broad protection and potential for strategic design-around efforts.
The patent landscape reveals active competition and ongoing innovation, with subsequent patents refining or diverging from the original scope. As the patent approaches expiration, market entries for generics or biosimilars are likely to increase, provided infringing compositions are carefully monitored.
Stakeholders—including originators, generic manufacturers, and academia—must evaluate this patent’s claims against their formulations, considering licensing, design-around strategies, or potential expiration-driven market opportunities.
Key Takeaways
- Scope: The patent covers a broad class of absorption-enhancing compositions, making it highly relevant for oral drug delivery systems.
- Claims: Encompass compositions, processes, and uses, with specific emphasis on combining APIs with absorption enhancers and carriers.
- Patent Landscape: Active citations and subsequent filings indicate a dynamic field, with ongoing innovation stemming from or diverging from US 6,835,739.
- Expiration: Due for expiration in December 2024, leading to increased competition and opportunity in biosimilar development.
- Strategic Advice: Companies should assess formulation strategies that avoid infringement, monitor related patents, and consider licensing or collaboration opportunities prior to expiration.
FAQs
1. What are the primary classes of absorption enhancers covered by US 6,835,739?
Primarily surfactants, bile salts, fatty acids, and polymeric agents known to increase permeability or solubilization of APIs.
2. How does this patent compare to lipid-based delivery patents?
While lipid-based patents focus on lipid formulations for bioavailability, US 6,835,739 broadly claims compositions with various absorption enhancers, including but not limited to lipids.
3. Are there legally equivalent patents or patents that explicitly challenge US 6,835,739?
Notably, subsequent patents have built upon or designed around it, with no prominent legal challenges publicly known to have invalidated its claims as of 2023.
4. Is the patent enforceable for existing generic drug formulations?
Potentially, if the formulations or processes infringe the broad claims; enforcement depends on specific composition analysis.
5. What formulation strategies can circumvent this patent?
Using different classes of absorption enhancers outside those claimed, or alternative delivery methods such as iontophoresis or targeted nanoparticles not explicitly covered.
References:
[1] U.S. Patent 6,835,739, "Pharmaceutical Composition for Improved Absorption," Hoechst Marion Roussel Inc., Dec. 28, 2004.
[2] prior art lipid-based patents (e.g., US 5,580,548).
[3] International Patent Classification (IPC) codes: A61K 9/00, A61K 47/00, A61K 31/00.
More… ↓
⤷ Start Trial
|
